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Abstract
Development of the retinal vascular network is strictly confined within the neuronal retina, allowing the intraocular media to
be optically transparent. However, in retinal ischemia, pro-angiogenic factors (including vascular endothelial growth factor-
A, VEGF-A) induce aberrant guidance of retinal vessels into the vitreous. Here, we show that the soluble heparan sulfate
level in murine intraocular fluid is high particularly during ocular development. When the eyes of young mice with retinal
ischemia were treated with heparan sulfate-degrading enzyme, the subsequent aberrant angiogenesis was greatly
enhanced compared to PBS-injected contralateral eyes; however, increased angiogenesis was completely antagonized by
simultaneous injection of heparin. Intraocular injection of heparan sulfate or heparin alone in these eyes resulted in reduced
neovascularization. In cell cultures, the porcine ocular fluid suppressed the dose-dependent proliferation of human
umbilical vein endothelial cells (HUVECs) mediated by VEGF-A. Ocular fluid and heparin also inhibited the migration and
tube formation by these cells. The binding of VEGF-A and HUVECs was reduced under a high concentration of heparin or
ocular fluid compared to lower concentrations of heparin. In vitro assays demonstrated that the ocular fluid or soluble
heparan sulfate or heparin inhibited the binding of VEGF-A and immobilized heparin or VEGF receptor 2 but not VEGF
receptor 1. The recognition that the high concentration of soluble heparan sulfate in the ocular fluid allows it to serve as an
endogenous inhibitor of aberrant retinal vascular growth provides a platform for modulating heparan sulfate/heparin levels
to regulate angiogenesis.
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Introduction
The exposure of the retina to various insults such as chronic
elevation of blood glucose or sudden exposure to high oxygen
induces obliteration of pre-existing retinal vascular structures. It is
often followed by the extension of retinal vessels from the border of
the avascular retina into the vitreous cavity, which triggers a string
of events that ultimately compromise vision. Pathologies that arise
from these insults include diabetic retinopathy or retinopathy of
prematurity, both of which are growing concerns worldwide
because of the alteration in diet and lifestyle or the increased
survival of premature infants due to advancements in neonatal
medicine. While angiogenesis is strictly confined to the retina
during development, little is known about why vascular regener-
ation favors aberrant extension into the vitreous in ischemic
retinopathies.
Heparan sulfate (HS) proteoglycans are composed of a core
protein and one or more sugar chains with specific patterns of
linear polysaccharides called glycosaminoglycan (GAG) [1].
These proteoglycans are expressed ubiquitously on the surface
of all cell types as transmembrane or membrane-anchored
protein or within the extracellular matrix as secreted forms,
critical for various physiological processes. Numerous sulfations
present within the sugar chains provide a strong negative
charge, allowing interaction with various heparin-binding
proteins and their receptors [1]. Genetic ablation studies have
revealed the specific role of each HS proteoglycan that depend,
at least partly, on localization [2] .A s i d ef r o mt i s s u es p e c i f i c i t y ,
compelling evidence indicates that membrane-associated HS
promotes the interactions of various heparin-binding growth
factors, including vascular endothelial growth factor-A (VEGF-
A), to their receptors [3,4]. However, the role of soluble HS in
the interactions appears to be more dependent on the context,
such as cell type, tissue, or its own concentration, and is bivalent
at times, making interpretation difficult [5,6]. The binding of
soluble GAGs to the cell surface converting them to the
membrane-associated form also contributes to the complexity
[3]. For example, constitutive expression of the soluble HS
proteogylcan, shed syndecan-1, decreased the proliferation of
MCF-7 adenocarcinoma cells [6] while exposure of T47D
ductal carcinoma cells to secreted syndecan-1 stimulated their
proliferation [7]. Lower concentrations of soluble HS GAGs in
culture media significantly promoted the binding of VEGF-A to
cultured melanoma cells, while an opposite effect has been
recognized at higher concentrations [8]. The function of a
particular soluble HS proteoglycan in vivo is even harder to
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p r o t e o g l y c a n si sl e s sd e p e n d e n to nt h et y p eo fc o r ep r o t e i n ,a n d
the loss of a particular proteoglycan may be compensated by
others.
The aqueous humor is a clear fluid that circulates the anterior
compartment of the eye. It is actively produced in the posterior
chamber by the non-pigmented ciliary epithelium and flows
anteriorly through the pupil and reabsorbs through the collector
channel in the angle. Estimation indicates about 1% turnover in
aqueous volume per minute. The chemical content of the aqueous
humor closely reflects the molecules found in the vitreous [9] but
the concentrations are always lower in the former; this is likely
mediated through gradient-driven anterior diffusion [9,10].
Evidence suggests that soluble HS in the aqueous humor harbors
an anti-angiogenic property, inhibiting the binding of pro-
angiogenic factors (VEGF-A and basic fibroblast growth factor)
to their cell surface receptors [11]. However, the physiological
significance of soluble HS in the eye remains to be demonstrated.
In this study, the role of soluble HS/heparin GAGs on retinal
angiogenesis was investigated. We found that the sufficiently high
concentration of soluble HS in the ocular fluid serves as a potent
endogenous inhibitor of aberrant growth of vessels from retinal
surface into the vitreous. The results suggested that this occurs
partly through inhibition of VEGF-A-receptor interaction and
signaling.
Results
Heparan sulfate in the aqueous humor is increased
during development
Newborn mice lack vascular structures in their retinas.
Developing retinal vessels grow radially from the optic nerve
toward the periphery along the vitreo-retinal interface, followed by
the formation of a deeper vascular plexus over the first 2 weeks
after birth. We first assessed the composition of HS proteoglycans
secreted in the ocular fluid from a mouse aged Post-natal day 15
(P15). An antibody that detects the urinate residues on the HS core
proteins created by the treatment of heparinase III resulting in a
specific degradation of HS GAGs was used (Figure 1A) [12]. As
with the previous report on vitreous samples from chickens [13],
multiple HS core proteins were observed. Soluble agrin, collagen
XVIII, or syndecans 1, 2, and 3 were deduced based on their
molecular weights from previous reports [14,15]; many of these
proteoglycans have been reported to be expressed in the retina
[13,16–18]. Next, we studied the concentrations of HS GAGs in
the ocular fluid collected from mice ranging in age from P7 to P60
using an enzyme-linked immunosorbent assay (ELISA) that
specifically detects HS polysaccharides (Figure 1B). The level of
HS was much higher in younger mice compared to older mice; the
level was 15.8-fold higher at P17 compared to P60. The HS
concentration in ocular fluid appeared to be uniquely high
Figure 1. HS GAG is increased in ocular fluid. (A) Profile of HS proteoglycans in the ocular fluid. Western blotting of the ocular fluid from P15
mice revealed multiple bands that presumably correspond to agrin, collagen XVIII, syndecan-3, syndecan-1, and syndecan -2 [14,15]. (B) Time-course
profile of HS concentration in ocular fluid. HS level was increased in younger mice (P7, P12, and P17; N=6 each) compared to older animals (P60;
N=5). (C) Comparison of HS concentration among body fluids. HS level was higher in ocular fluid compared to plasma or urine at P17 (N=7) and P60
(N=5), respectively. (D) GS staining of retinal quadrants in the OIR model. At the beginning of O2 exposure (P7), retinal vessels are extending toward
the periphery (asterisk). The retinal vessels obliterate and regress (outlined by arrows) after exposure to 80% oxygen (P12). Returning the mice to
room air results in outgrowth of extra-retinal NV at P17 (NV tufts are outlined by arrowheads in inset). Note that clumps of extra-retinal NV show
stronger GS staining compared to intra-retinal vessels. (E) Comparison of HS concentration between samples from OIR and wild-type (WT) mice (N=7
each). No difference was detected. ON: optic nerve. All statistical data are expressed as mean 6 standard error of the mean (S.E.M.).
doi:10.1371/journal.pone.0013493.g001
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fold higher at P17 and P60, respectively) or urine (236-fold and 30-
fold higher at P17 and P60, respectively) from the same mice
(Figure 1C).
The exposure of mouse pups (P7) to 80% oxygen for 5 days
results in an extensive obliteration and drop-out of the retinal
vasculature around the optic nerve (Figure 1D). This is due partly
to the rapid down-regulation of VEGF-A by retinal parenchyma
[19] and oxidative insults [20]. Subsequently returning these mice
to room air for another 5 days results in the up-regulation of
VEGF-A from the non-perfused retina [21,22] and the develop-
ment of extra-retinal neovascularization (NV) and intra-retinal
revascularization (oxygen-induced retinopathy, OIR; Figure 1D)
[23]. With a hypothesis that the secreted HS level may be
differently regulated during active pathologic angiogenesis, we
measured HS concentrations in the ocular fluid and plasma in
mice with OIR. However, no difference was detected between
samples from an OIR model and control mice (Figure 1E).
HS/heparin GAGs inhibit the development of
extra-retinal NV in vivo
In order to determine the role of HS GAGs in the ocular fluid,
we applied heparinase III to non-specifically remove HS
polysaccharides from the core protein. First, the efficacy of
heparinase III as an endoglycosidase was determined. HS
concentration was reduced by 87.3% when the enzyme was
injected into the eyes in vivo and by 80.2% when the murine ocular
fluid was incubated with heparinase III in vitro (Figure 2A). To
elucidate the role of HS in physiological retino-vascular develop-
ment in vivo, we injected heparinase III into the developing eyes at
P3, when the vessels covered only a small proportion of the retina.
Subsequent examination of the retina at P5 and P8 showed no
difference in the area of vascularized tissue between the
phosphate-buffered saline (PBS) - and heparinase III-treated eyes
(Figure 2B and C). Intraocular injection of a high dose of
exogenous HS GAGs purified from bovine kidney (resulting in
,12,500 mg/ml in the eye) showed no detectable influence on the
retinal vascular development (Figure 2D). Next, we evaluated the
effect of HS degradation on pathologic angiogenesis in an OIR
model. Heparinase III was injected into the eyes at P12
immediately after returning the mice to room air (at the end of
5 days’ exposure to 80% oxygen). At P17, the degradation of HS
by heparinase III dramatically increased the area of pathological
NV by 2.9-fold compared to the PBS-treated contralateral eye
(Figures 2F and 2J); this effect was completely abrogated by
simultaneously injecting heparin, a heparinase III-insensitive GAG
(Figures 2G and 2K). While heparin lacks the core protein, there is
no qualitative difference between heparin and HS chains in their
binding properties [24]. Therefore, the results strongly indicate
that the inhibition of NV is mostly due to sugar chains and less
dependent on the types of core protein. To extend this observation
and see if HS or heparin GAG injection can negatively regulate
pathologic angiogenesis, purified HS chains without the core
protein or heparin alone were administered into the eyes with OIR
at P12. As predicted, we observed a reduction of pathological NV
by 64.2% with the administration of high-dose HS (,12,500 mg/
ml in the eye; Figures 2H and 2M), while the effect was variable
and not evident at a lower dose (,1,250 mg/ml in the eye;
Figure 2L) at P17. The injection of high-dose heparin
(,12,500 mg/ml in the eye) in mice with OIR yielded a similar,
but more potent (reduction of NV by 80.8%), and less variable
effect (data not shown; Figures 2I and 2N). Endogenous heparin is
produced exclusively by mast cells and basophils, but these cells
are uncommon in the vitreous or retina. Accordingly, no effect was
detected when the heparinase I endoglycosidase that targets
heparin but not HS GAGs was injected (Figure 2O).
The influence of HS/heparin GAG modulation on the area of
avascular retina (thus intra-retinal revascularization) was minimal
(Figures 2J–O). Only high-dose HS injection showed a modest, but
significant, effect on the area of avascular retina (reduction by
13.4%; Figure 2M). Administration of all other agents revealed no
effect on this parameter.
VEGF-A is paradoxically elevated in eyes injected with
heparin
VEGF-A, a heparin/HS-binding glycoprotein, is the major pro-
angiogenic growth factor that controls the development of extra-
retinal NV in OIR [21,22,25]. The dominant role of this protein in
theOIR modelwasconfirmedbytheintraocularinjectionofsoluble
VEGF receptor 1 (VEGFR1), a potent antagonist of VEGF-A,
which resulted in 98.0% reduction in NV (Figure S1). Since HS/
heparin GAGs are known to influence VEGF-A signaling, it is
important to study the interactions of the related molecules to
furtherunderstand the mechanisticbasisfortheanti-angiogenicrole
of soluble GAGs in the eye. First, we analyzed the level of VEGF-A
in the ocular fluid in an OIR model and in wild-type controls.
VEGF-A concentrations in the ocular fluid were reduced with
exposureto80%oxygenatP8andP12 (Figure 3A). The subsequent
introduction of the mice to room air rapidly increased VEGF-A
level, resulting in 9.7-fold higher concentration compared to that of
controls at P14. These observations are consistent with the reported
alteration of VEGF-A production in the retina of OIR mice
[19,21,22]. Next, we studied VEGF-A levels in the ocular fluid at
P14, two days after the administration of heparinase III at P12
(immediately after returning the mice to room air), where elevated
VEGF-A levels in OIR was not affected by heparinase III
treatment, i.e., no difference was detected compared with PBS-
treated eyes (Figure 3B). However, the ocular fluid from the
heparin-injected eyes revealed a further 11.3-fold increase in
VEGF-A concentration compared with the control OIR eyes with
high VEGF-A levels (Figure 3C). Similarly, VEGF-A levels in the
ocular fluid were increased by 2.6-fold (P,0.001) in the eyes
injected with high-dose HS (4,0856232 pg/ml: mean 6 S.E.M.)
compared with PBS-treated OIR eyes (1,550694 pg/ml). These
paradoxical observations showing greatly increased VEGF-A in the
heparin- or HS-treated eyes with reduced NV indicated that GAGs
inhibit the function of VEGF-A as a vascular endothelial mitogen.
VEGF165 binding to heparin inhibits its degradation
In order to explore the etiology of this paradoxical observation,
we sought an explanation for the increased VEGF-A. First, retinal
mVegf-A mRNA from P14 OIR mice injected with heparin or
PBS at P12 was quantified. There was no obvious difference in the
level of mVegf-A transcription between the eyes treated with
heparin or PBS (P=0.199; 1.260.7 or 4.562.5 fold-copies
mCyclophilin A, repectively). This indicated that increased
VEGF-A in the ocular fluid of heparin-treated eyes occurred by
post-transcriptional mechanisms. VEGF-A isoforms, VEGF164
(VEGF165 in humans), and VEGF120 (VEGF121 in humans), are
expressed during development of the retinal vasculature [22,26].
VEGF164/165 is the major functional isoform that contains the
heparin-binding domain. VEGF120/121 is the shorter isoform
without this domain. Next, the kinetics of VEGF-A in murine eyes
were examined by injecting human isoform VEGF121 or
VEGF165 alone without heparin in one eye and with heparin in
the other eye. Then the ocular fluid was collected 6 and 48 hours
later and the remnant of injected VEGF-A was measured with an
ELISA that detected only human isoforms. At 6 hours after the
GAGs in Retinal Angiogenesis
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13493Figure 2. HS/heparin GAGs inhibit the development of NV in OIR. (A) Breakdown of HS GAGs by heparinase III (HIII). HIII reduced HS in the ocular
fluid by 87.3% in vivo (left; N=5) and 80.2% in vitro (right; N=5). (B–C) Measurement of area covered with retinal vessels. Representative images of GS-
stainedretinas from P5(B; N=6)orP8(C;N=6)micetreatedwithPBS orHIIIatP3are shown and the proportionofvascularizedareaoverthe entireretina
was quantified (%). Similarly, proportion of vascularized retina was measured in P5 mice treated with PBS or HS at P3 (D; N=6). No difference was
detected.(E–I)RepresentativeappearanceofGSstainingoftheretinatreatedwithPBS(E),HIII(F),HIIIandheparin(HIII+Hep;G),high-doseHS(HS-hi;H),or
heparin (Hep; I) at P12 and analyzed at P17 (upper images). The same images were highlighted in red and blue for NV and avascular area, respectively.
(lower images). (J–O) Quantification of NV area (upper panels) and avascular retina (lower panels) expressed as area relative to entire retina (%). The eyes
GAGs in Retinal Angiogenesis
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eye injected with heparin compared to the contralateral eye
without (Figure 3D). Meanwhile, no difference in human
VEGF121 level was detected between the eyes that received
VEGF121 with or without heparin. At 48 hours after the
injection, both isoforms were undetectable regardless of heparin
co-administration (Figure 3E). The prolonged retention of
VEGF165 by heparin but not VEGF121 is compatible with the
direct binding of heparin to the heparin-binding domain of
VEGF165 contributing to the phenomenon. Plasmin is a serine
protease that is expressed in the eyes [27] and is known to cleave
or degrade VEGF-A into smaller fragments [28,29]. We tested
whether heparin binding to VEGF-A can result in resistance to
proteolysis by plasmin in vitro. Heparin inhibited the plasmin-
mediated breakdown of the VEGF165 isoform (Figure 3F), but not
VEGF121 (Figure 3G). Taken together, these results indicate that
heparin-VEGF165 binding contributes to an increased intraocular
VEGF-A concentration, at least partly through the inhibition of
VEGF165 degradation by endogenous proteases such as plasmin.
High level of soluble heparin inhibits proliferation,
migration, and tube formation of vascular endothelial
cells
Next, we assessed the effect of ocular fluid and soluble heparin
on the VEGF-A-mediated viability of human umbilical vein
were treated with HIII (N=9), HIII+Hep (N=8), low-dose HS (HS-lo; N=8), HS-hi (N=8), Hep (N=7), and heparinase I (HI; N=6). Note increased NV in the
eyes treated with HIII (J), which was antagonized by co-injection of Hep (K). NV was decreased by intra-ocular injection of HS-hi (M) or Hep (N), while no
difference was detected with HS-lo (L) or HI (O) administration. All statistical data are expressed as mean 6 S.E.M.
doi:10.1371/journal.pone.0013493.g002
Figure 3. Soluble heparin-bound VEGF-A is inactivated but is also protected from proteolysis. (A) VEGF-A levels in the ocular fluid in OIR
mice. VEGF-A concentration was determined at P8, P12, and P14 from wild-type control (WT) and OIR model, respectively (N=6 each). (B,C) VEGF-A
levels in the ocular fluid collected at P14 from OIR mice treated with heparinase III (HIII; N=8) or heparin (Hep; N=7) at P12. Intra-ocular heparin
injection resulted in greatly increased VEGF-A levels (C) while levels were not affected by HIII treatment (B). (D,E) Kinetics of human VEGF-A in murine
eyes at 6 and 48 hours after intraocular injection. Human isoform VEGF121 (5 ng/eye) was injected with heparin (20 mg/eye) in one eye and without
in the other at P12. Ocular fluid was analyzed with human VEGF-specific ELISA at 6 and 48 hours later (N=6 and N=5, respectively). An identical
experiment was conducted using human VEGF165 (5 ng/eye; N=6 each). Only eyes co-injected with VEGF165 and heparin and analyzed at 6 hours
post-injection showed increased human VEGF-A (D). The left and right vertical axes show concentration (ng/ml) and proportion (% relative to injected
amount) of the remaining VEGF-A in the ocular fluid, respectively. Human VEGF-A was not detected in the uninjected control (N=6). (F,G) The effect
of heparin on in vitro degradation of VEGF-A by plasmin. VEGF165 (F), or VEGF121(G) was subjected to proteolysis by plasmin (400, 80, 16, and 3.2 ng
for lanes 1 and 5, 2 and 6, 3 and 7, and 4 and 8, respectively). Undigested VEGF121 and VEGF165 were applied as references (arrowheads). All
statistical data are expressed as mean 6 S.E.M.
doi:10.1371/journal.pone.0013493.g003
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reproducing the unique ocular environment in which acellular
vitreous/ocular fluid overlays the plane of retinal vascular
network. HUVECs were incubated with increasing concentrations
of heparin in a standard endothelial culture media (EG2)
supplemented with VEGF-A. The viability of HUVECs showed
an inverse dose response to heparin, which revealed 31.2%
reduction in optical density (OD) measurements at a heparin level
(1,000 mg/ml) relevant to the HS concentrations in the ocular fluid
from OIR models (Figure 4A).
Next, the viability of HUVECs cultured in PBS, EG2, or
porcine ocular fluid with or without VEGF-A (10 ng/ml) was
assessed (Figure 4B). While few HUVECs survived in PBS alone,
ocular fluid maintained the viability of the cells (albeit to a lesser
degree when compared to EG2). Only HUVECs cultured in EG2
were sensitive to VEGF-A stimulation. A dose-response curve
showed a positive correlation between VEGF-A level and the
viability of HUVECs in EG2 media (Figure 4C). Conversely,
HUVECs were unresponsive to VEGF-A when incubated in
ocular fluid. These results are compatible with the inhibition of
VEGF-A signaling by soluble GAG as one of the mechanisms for
the anti-angiogenic effects of ocular fluid.
In order to further assess the effect of heparin and ocular fluid
on the functional aspects of vascular endothelial cells, we first
evaluated the migration of HUVECs induced by creating an
artificial groove in the middle of the well. Heparin suppressed the
migration of the cells into the groove in a dose dependent manner
in media with or without VEGF-A (1,000 pg/ml; Figure 4D and
4E). However the inhibitory effect was less pronounced in the
former. Ocular fluid also suppressed the migration of HUVECs.
Next, we assessed the in vitro tube formation by HUVECs
(Figure 4F–K). While heparin increased the length of tubular
network and number of branch points, thus enhanced the tube
formation, at lower concentration (10 mg/ml), the presence of
higher concentration of heparin (1,000 and 10,000 mg/ml) or
ocular fluid inhibited the formation (Figure 4J and 4K). We found
similar but less inhibitory effects when VEGF-A (1,000 pg/ml) was
added to the medium. Notably, no tube structure was formed
under highest heparin concentration and ocular fluid when no
VEGF-A was added. Meanwhile, trace evidence of tube formation
was observed in ocular fluid under the presence of VEGF-A
(Figure 4F–K). The results of cell-based assays conformed well to
the results of in vivo injection studies showing suppression of
angiogenesis by endogenous HS in the ocular fluid and further
reduction achieved by exogenously administered GAGs, but only
at higher concentrations.
High level of soluble heparin inhibits binding of VEGF-A
and HUVECs
The results of in vivo and cell-based experiments suggest that
administration of soluble HS/heparin inhibits angiogenesis, in
part, by blocking the functional activity of VEGF-A. In order to
investigate the mechanistic basis for this observation, we assessed
the interaction of VEGF-A and HUVECs (Figure 4L–N). We
found that the lower concentrations of heparin (10 and 100 mg/ml)
enhanced the binding of VEGF-A and HUVECs by , 4-fold
compared to the condition without heparin; this effect decreased
dramatically with increasing concentration of heparin. At the
highest concentration studied (10,000 mg/ml heparin), VEGF-A
bound to HUVECs were decreased by 72.9% compared to the
control with no heparin. Meanwhile, in the presence of ocular
fluid, VEGF-A bound to HUVECs with similar efficiency as the
control condition.
Soluble heparin inhibits the binding of VEGF165 to
surface heparin
In order to further delineate the roles of surface-associated
versus soluble GAGs on VEGF-A at a molecular level, wells were
covalently crosslinked with heparin and the kinetics of VEGF-A-
heparin binding under the presence or absence of soluble heparin
were investigated with in vitro binding assays. When a constant
amount of soluble VEGF-A was applied alone, surface-bound
VEGF-A was positively correlated with the amount of heparin
coating on the well bottom (Figure 5A). This finding corroborates
the fundamental role of surface GAGs to provide docking sites on
the cell surface for heparin-binding growth factors (including
VEGF-A). Next, we studied the effect of soluble heparin on the
binding of VEGF-A and immobilized heparin. An increasing
concentration of heparin and a constant level of VEGF-A were
added to a fixed amount of well-coated heparin. Soluble heparin
suppressed the binding of VEGF-A and surface heparin dose
dependently (Figure 5B). The binding was inhibited by 87.9% with
1, 000 mg/ml of soluble heparin. Parallel experiments showed that
the bindings of VEGF-A and surface-heparin were inhibited also
by the presence of soluble HS or porcine ocular fluid (Figure 5C).
To further characterize the nature of ocular fluid as an inhibitor
of VEGF-heparin binding, a dose-binding curve was plotted by
applying increasing concentrations of VEGF165 dissolved in PBS
or porcine ocular fluid to heparin-coated wells (Figure 5D).
Consistent with earlier experiments, the binding of VEGF-A and
surface heparin was suppressed by ocular fluid. The result of
regression analyses was compatible with the rightward shift of the
binding curve with the presence of the ocular fluid (P,0.001;
R
2=0.976). This strongly indicates that the ocular fluid interferes
with the association of surface heparin and VEGF-A by competing
for the same heparin-binding domain of VEGF-A.
Soluble HS/heparin GAGs inhibit the binding of VEGF165
and VEGF receptor 2 (VEGFR2)
VEGFR1 and VEGFR2 are well characterized receptors for
VEGF-A. VEGFR2 is the key receptor for endothelial prolifer-
ation and migration [30]. VEGFR1, with more variable effects on
endothelial cells, serves as a decoy receptor to regulate the activity
of VEGF-A [30]. Both VEGFR1 and VEGFR2 are heparin-
binding proteins [31,32]. In order to define the role of soluble HS/
heparin on the binding of VEGF-A and its surface receptors,
VEGFRs were crosslinked to the bottom of wells and soluble HS
GAGs or porcine ocular fluid were added with a fixed amount of
VEGF-A. Soluble heparan sulfate or the ocular fluid inhibited the
binding of VEGF165 and VEGFR2 (Figure 5E); in contrast,
VEGF121-VEGFR2 association was not influenced (Figure 5F).
Next, a constant level of VEGF-A (VEGF165 or VEGF121) and
an increasing amount of heparin were applied to VEGFR2-coated
wells. Soluble heparin inhibited the binding of VEGF165 and
VEGFR2 in a dose-dependent manner, while showing minimal
effect on VEGF121-VEGFR2 interaction (Figure 5G). At the
heparin concentration of 1,000 mg/ml, the binding of VEGF165
or VEGF121 and VEGFR2 was reduced by 59.8% or 9.4%,
respectively.
Parallel experiments to assess the effect of soluble GAGs on
VEGF-A-VEGFR1 interaction revealed only modest or no
suppression by HS, ocular fluid, or heparin, in every condition
tested (Figures 5H–J).
Taken together, our results suggest that soluble HS/heparin
GAGs or ocular fluid can directly prevent the binding of
VEGF165 to VEGFR2, but not VEGF121. Meanwhile, the
inhibition of VEGF165-VEGFR1 interactions was less evident.
GAGs in Retinal Angiogenesis
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13493Figure 4. Heparin and ocular fluid inhibit proliferation of HUVECs. (A) Effect of heparin on the viability of HUVECs. Various concentrations of
heparin were added to the cells in EG2 media supplemented with VEGF-A (10 ng/ml). Note viability of HUVECs is suppressed by soluble heparin in a
dose-dependent manner. The experiment was done in quadruplicate and repeated. (B) Comparison of viability among HUVECs cultured with
different medium. Note that viability of HUVECs is increased with addition of VEGF-A (10 ng/ml) when cultured with EG2 media but not with PBS or
ocular fluid (N=6 for each condition). Viability was low when cultured with PBS. The experiment was repeated. (C) Viability of HUVECs cultured in EG2
media or ocular fluid (OF) with increasing concentrations of VEGF-A. Note that a positive dose-response relationship was observed when cultured in
EG2 media, while HUVECs were unresponsive to VEGF-A in the ocular fluid. OD measurements relative to a condition without heparin (A) or VEGF-A
(C) are shown in percentages (%). Experiments were done in quadruplicate and repeated. (D,E) Effect of heparin and ocular fluid on scratch wound
induced migration of HUVECs. Representative images of HUVECs 24 hrs after creating scratch wound (D). Groove was larger when cells were
incubated with ocular fluid (lower panel) compared with PBS (upper panel). Dose-dependent inhibition of cell-migration by heparin was observed
GAGs in Retinal Angiogenesis
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In this study, we analyzed the role of soluble HS GAGs in an
intraocular environment in which the plane of vascular network is
embedded within the surface of the retinal parenchyma, but is also
adjacent to the overlying ocular fluid that contained a high level of
HS.
Roles of endogenous HS as a suppressor of extra-retinal
angiogenesis
Earlier studies showed presence of HS in the retina including
collagen XIII, agrin, glypicans,and syndecans. [18] Forexample,
the expression of syndecan 3 was increased during ocular
development detected by immunohistochemistry. [16,17] Gan-
glion cells, amacrine cells, and horizontal cells were shown to be
the main source of syndecan 3, [16] which was also found in the
ocular fluid. In the current study, concentration of soluble HS
GAGs in the ocular fluid presumably derived from intraocular
structures including the retinal parenchyma was quantified. We
found extremely high levels of HS in the ocular fluid during
ocular development compared to plasma or urine from the same
group of mice, ocular fluid from adult mice, or reported HS levels
in bovine aqueous humor [11]. This temporal expression profile
simulated that reported for syndecan 3. [16] In this unique
intraocular setting, the high concentrations of endogenous
soluble HS GAGs appear to act as suppressors of pathologic
angiogenesis, particularly under excessive amount of VEGF-A
driven by retinal ischemia. In vitro studies suggested the ocular
fluid and relevant levels of soluble GAGs could compete for
VEGF-A with its surface counterpart that function as co-
receptors for VEGFR2 or by directly interfering with ligand-
receptor interactions. Since VEGFR2 is responsible for vascular
endothelial proliferation and migration, suppression of VEGF-A-
VEGFR2 interaction by soluble HS in the ocular fluid renders
protection of the intra-vitreal environment from aberrant
invasion of retinal vessels. The binding of VEGF-A and
VEGFR1 was minimally affected by soluble GAGs suggesting
that the binding affinity of this ligand-receptor is probably much
higher than that of VEGF-A and GAGs. The relative increase in
signaling of VEGFR1 over VEGFR2 may provide an additional
advantage by defending retinal vessels from vaso-obliteration
[33]. Meanwhile, modulation of the HS level in the vitreous
cavity posed minimal influence on intra-retinal vascular growth
during physiological development and vascular regrowth in OIR.
These findings suggest that the anti-angiogenic property of
soluble HS in ocular fluid preferentially inhibit extra-retinal
extension of vessels, which corroborates with the unique
distribution of ocular fluid. However, since significant amount
of soluble HS (,12.7%) still remain after the application of HS-
degrading enzymes in the current experimental setting, further
investigation is required to draw a conclusion on the role of
soluble HS in intra-retinal vascularization.
Potential of soluble GAGs as inhibitors of angiogenesis
Intraocular injection of soluble GAGs resulted in a reduced
pathologic NV formation in OIR, showing a treatment effect for
the ischemia-induced retinal vaso-proliferative disease in vivo.
However, extremely high levels of GAGs (,12,500 mg/ml in the
eye) were required to achieve a clear therapeutic benefit. This was
in agreement with the results of cell-based and in vitro binding
assays showing that only higher doses of soluble heparin
suppressed the angiogenic properties of HUVECs and interactions
of VEGF-A and related molecules more efficiently than the ocular
fluid. Meanwhile, the effects of lower concentrations of heparin
was variable rendering both increased and decreased activity of
HUVECs or interaction of VEGF-A that appeared to be
dependent largely on the experimental conditions. These obser-
vations may explain somewhat inconsistent roles of heparin on
angiogenesis and VEGF-A interactions proposed by different
groups using lower doses of heparin [4,34–36].
Meanwhile, a discrepancy between the level of HS in the ocular
fluid and its ability to inhibit angiogenesis and molecular
interactions of VEGF-A was noted. For example, inhibitory effect
of ocular fluid (63.2 mg/ml of HS) on VEGF-A-VEGFR2 binding
(,85.7% inhibition) was comparable to 1,000 mg/ml of HS
(,88.1% inhibition) from bovine kidney in vitro. On the other
hand, in vitro experiments also demonstrated that anti-VEGF-A
feature of ocular fluid is due in part to competition with cell
surface GAGs for VEGF-A binding, which is most likely by soluble
GAGs found in the ocular fluid. As the structure/function of HS
sugar chains on the same core proteins differs significantly between
different organs or tissues [4,37], injected GAGs from extra-ocular
source used in this study may not have been as effective as those
from the ocular fluid. Alternatively, an another possibility is that
ocular fluid contains heparin-like substance that are different from
HS or a factor that cooperate with HS to inhibit angiogenesis and
function and molecular interaction of VEGF-A.
Molecular mechanisms of functional inhibition of VEGF-A
by GAGs
While addition of high levels of soluble GAGs was shown to exert
anti-angiogenic effect and suppression of VEGF-A function, soluble
GAGs can bind to cell surface and become membrane-associated.
Therefore, the exact relationship between the spatial distribution of
GAGsand VEGF-A with regardto the vitreo-retinal interface during
the functional inhibition of VEGF-A by GAGs remains unclear.
Similarly, mechanisms underlying heparinase III-mediated enhance-
ment of pathological NV are unknown. Enzyme treatment likely
results in the break-down of both soluble and surface HS. However,
several lines of evidence suggested that presence of soluble GAGs in
the fluid are important in the inhibition of pathological angiogenesis
in OIR. First, the administration of soluble GAGs resulted in their
binding to and retention of VEGF-A within the murine ocular fluid.
Second, in vitro binding assay showed that administration of soluble
GAGs inhibited the interaction of surface GAGs and VEGF-A.
with or without co-administration of VEGF-A (E). The assay was done in triplicate and repeated. (F–K) Effects of heparin and ocular fluid on tube
formation of HUVECs. Representative images of HUVECs cultured in media with 0 (F), 1,000 (G), and 10,000 (H)mg/ml heparin or in ocular fluid (I), all of
which contained VEGF-A. Note that only 10,000 mg/ml heparin completely suppressed tube formation. The degree of tube formation was quantified
by measuring tube length (J) and counting branch points (K). At the lowest dose tested, heparin promoted the tube formation while an opposite
effect was observed at higher doses in culture media. Note that ocular fluid suppressed angiogenesis incompletely and completely with and without
VEGF-A, respectively. The assays were conducted in triplicate and repeated. (L–N) Effects of heparin and ocular fluid on the binding of VEGF-A and
HUVECs. Representative images of FACS analyses of fluorescein-labeled VEGF-A and HUVECs showing increased and decreased binding at 10 (M) and
10,000 (N) mg/ml heparin (purple) compared to condition without heparin (white), respectively. Analysis showed that presence of lower
concentrations (10 and 100 mg/ml) of heparin promoted the bindings while showing inhibitory effect at the highest dose (10,000 mg/ml; N). Each data
point is an average of two measurements. The experiment was repeated. Data presented in (A–C,) (E), (J), and (K) are expressed as mean 6 S.E.M.
Scale bars indicate 1 mm.
doi:10.1371/journal.pone.0013493.g004
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PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13493Figure 5. Soluble HS/heparin GAGs inhibit the binding of VEGF165 to immobilized heparin and VEGFR2. (A) Binding of VEGF-A and
increasing amounts of immobilized heparin (horizontal axis). (B) Influence of soluble heparin on binding of VEGF-A and immobilized heparin. VEGF-A
was applied with an increasing level of soluble heparin (horizontal axis) to a fixed amount of surface-coated heparin. (C) Binding of immobilized
heparin and VEGF-A applied with soluble HS GAGs or ocular fluid (OF). Note that low (HS-lo;100 mg/ml) or high (HS-hi; 1000 mg/ml) concentrations of
HS or OF reduced the binding of VEGF-A and immobilized heparin. (D) An increasing level of soluble VEGF-A and its association with immobilized
heparin. VEGF-A (horizontal axis) was dissolved in PBS or OF. Regression analyses of VEGF-A in OF were consistent with rightward shift of the curve
plotted with VEGF-A in PBS. (E–J) Influence of OF, soluble HS, or soluble heparin on the binding of VEGF165 or VEGF121 and immobilized VEGR2 (E–G)
or VEGFR1 (H–J), respectively. Binding of VEGF165 and immobilized VEGFR2 was significantly inhibited with HS-lo, HS-hi, OF (E) and heparin (G).
Meanwhile, binding of VEGF165 or VEGF121 and VEGFR1 was only modestly inhibited by HS/heparin GAGs or OF (H–J). Values relative to controls (%)
are shown in (B), (C), and (E–J). Representative data from three experiments analyzed with an online software (http://zunzun.com) is presented in (D).
For all other data, experiments (N=6 for each data) were repeated and representative data are expressed as mean 6 S.E.M. *P,0.050.
doi:10.1371/journal.pone.0013493.g005
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was not investigated, it is likely that inhibition of the interaction
occurred at the liquid phase because the amount of surface-bound
VEGF was positively linked to that of surface-associated heparin in
this experimental condition. Third, the injected GAGs targeted the
pathological retinal vessels extending into the vitreous with high
specificity while showing minimal effect on physiological vasculatures
on the surface retina in vivo.
Both HS and heparin sugar chains share similar basic structures
and interact with the same heparin-binding proteins, often showing
similar effects. [1,24] This is consistent with the observation that
degradation of endogenous HS resulting in an increased patholog-
ical NV in OIR could be reversed by co-administration of heparin
in vivo. The GAGs also shared similar effect in their basic quality
toward the interaction of VEGF and surface GAGs or receptors.
However, there are differences between these GAGs that could
affect their affinities to a particular protein, thus efficiency of
physiological effect. For example, the degree of sulfation is higher in
heparin compared to HS resulting in greater negative charge
density.[1]Asionicinteractionplaysacentralroleintheinteraction
of GAGs and heparin-binding proteins, heparin has higher affinity
to these molecules compared to HS GAGs in general. We have
confirmed that the variable decrease inN- and O-sulfation of GAGs
doesreducetheirbindingtoVEGF-Ainvitro(datanotshown).This
could be one explanation for the observation that HS was less
efficient in blocking the function of VEGF-A and abnormal retinal
angiogenesis compared to heparin.
Disparities between VEGF-A level in the ocular fluid and
angiogenic activity
An increased VEGF-A level in the ocular fluid (11.3-fold
increase) in the heparin-injected eyes with reduced NV (reduction
by 80.8%) was observed in OIR models, which was attributable in
part to the resistance of heparin-bound VEGF-A to proteolysis,
but not increased transcription of mVegf. Possibly due to a similar
mechanism, an increase in VEGF-A level in cell culture media by
the addition of soluble heparin has been reported previously [28].
Meanwhile, degradation of endogenous HS by heparinase III
resulting in a 2.90-fold increase in ischemia-induced extra-retinal
NV formation induced no alteration of VEGF-A level. Together
with the results of cell-based and in vitro assays, it appears that the
soluble GAGs in the vitreous bind to VEGF-A and raise its level
while simultaneously neutralizing its function as an angiogenic
factor. Thus, the disparities between VEGF-A concentrations and
angiogenic activities are consistent with the presence of both
functionally active and inactive form of VEGF-A unbound and
bound with soluble GAGs, respectively. This indicates that the
VEGF-A level in the aqueous humor or vitreous fluid per se may
not accurately reflect the bioactivity of the VEGF-A signaling in
the eye. These findings provide direct implications on the rapidly
expanding use of anti-VEGF agents to treat vaso-proliferative
diseases rationalized by elevated levels of intraocular VEGF-A.
In conclusion, soluble HS GAGs in the ocular fluid serve as
endogenous inhibitors of aberrant retinal angiogenesis, partly
mediated by the inhibition of interaction between VEGF-A and its
receptors or HS GAGs on the cell surface. Our study provides a
platform for modulating soluble HS/heparin levels to promote or
inhibit angiogenesis in human disease.
Materials and Methods
Animals
All experimental procedures adhered to the ARVO Statement
for the Use of Animals in Ophthalmic and Vision Research and
the guidelines for the Use of Animals at Nagoya University School
of Medicine. The research protocol on the use of animals has been
approved by the Animal Facility Committee, Nagoya University
School of Medicine (Approval # 22139). C57BL/6J mice used
were kept under a 12-hour light–dark cycle. For the generation of
OIR, P7 mice were first exposed to 80% oxygen (Proox 110; Bio
Spherix Ltd., Lacona, NY, USA) for 5 days. Mice (P12) were then
returned to room air for another 2 or 5 days until analyzed. OIR is
a model for retinopathy of prematurity, which develops in
prematurely born infants exposed to high oxygen, essential for
life support. An agent was injected (0.5 ml) into one eye and PBS
(Gibco Laboratories, Grand Island, NY, USA) into the other (at
P3 or P12) after mice were anesthetized with intraperitoneal
injections of tribromoethanol (Sigma-Aldrich Corp., St. Louis,
MO, USA) at a dose of 250 mg/kg. The amounts of agents
administered per eye were 0.005 U for heparinase III, 5 mg for
low-dose HS, 50 mg for high-dose HS, 50 mg for heparin, and
0.005 U for heparinase I, and 0.005 U and 50 mg for co-injection
of heparinase III and heparin, respectively, unless indicated
otherwise. To minimize the variability of the experimental results,
a single litter of mice (5–9 mice) was analyzed for each experiment.
Materials
All VEGF-A used in this study were VEGF165 isoform unless
designated otherwise. The recombinant VEGF165 and VEGF121
werepurchased from PeproTechInc., (Rocky Hill, NJ,USA) forthe
degradation and binding assays. VEGF receptor 1 (VEGFR1) and
VEGFR2 were from R&D Systems Inc. (Minneapolis, MN, USA).
HS GAGs purified from bovine kidney were from Seikagaku Corp.
(Tokyo, Japan) and unfractionated heparin from porcine intestine,
heparinase III, heparinase I, and chondoroitinase ABC were from
Sigma-Aldrich Corp.. The murine plasmin was from Pierce
Biotechnology (Rockford, IL, USA) The ocular fluid was collected
andpooled from multipleporcine eyes(8-month-oldanimals)within
3 hours after the pigs were killed at a local slaughterhouse. After the
ocular fluid was sterile filtered, the concentration of pooled HS was
determined (63.2 mg/ml) and stored in 280uC. Porcine ocular fluid
was later used for cell-based and binding assays.
Western blotting and enzyme-linked immunosorbent
assay (ELISA) of samples from body fluids
The optic nerve was removed together with a small island of
sclera, choroid, and retinal pigment epithelium from the
enucleated murine eye. A pipette tip was quickly inserted into
the eye through the exposed retina, where the ocular fluid (2–5 mL
per eye; a presumed mixture of vitreous fluid and aqueous humor)
was aspirated. The ocular fluid were centrifuged at 13,000 g for 5
minutes and the supernatant was subjected to analysis.
The mouse urine was aspirated by applying a pipette in front of
the genitals before sacrificing the animal, and peripheral blood was
collected from the orbit after enucleation. The plasma was isolated
from whole blood by centrifugation of the sample at 13,000 g for 5
minutes. These samples were stored in 280uC until analyzed.
The level of VEGF-A in the body fluids were measured with
ELISA kits purchased from R&D Systems Inc and HS
concentrations in the body fluids with those from Seikagaku
Corp. according to the manufactuer’s protocols. For western
blotting of ocular fluid or aqueous humor, the samples were
additionally treated with heparinase III (1 U/ml) and chondor-
oitinase ABC (2 U/ml) in 5 mM calcium acetate and 50 mM
sodium acetate at 37uC overnight. After the samples were mixed
with equal volume of Laemmli buffer (Biorad Laboratories Inc.,
Hercules, CA, USA), they were boiled, subjected to sodium
dodecyl sulfate polyacrylamide gel electrophoresis using 4–20%
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condition. The protein was transferred to polyvinylidene fluoride
membrane using the i-blot system (Invitrogen, Carlsbad, CA,
USA). An antibody (3G10; 1:500; Seikagaku Corp.) that reacts
with unsaturated urinate/HS ‘‘stubs’’ generated by heparinase III
treatment was used to detect HS proteoglycans (12).
HS degradation assay
Mice were injected with heparinase III (0.005 U per eye) in one
eye and PBS in the other at P12. After the ocular fluid was
collected at P14, HS concentration was determined with ELISA
(in vivo assay).
The ocular fluid (1.5 ml) collected from P14 mice was mixed
with heparinase III (0.0025 U) or an equal volume of PBS, which
was incubated overnight at 37uC in 5 mM calcium acetate and
50 mM sodium acetate (final volume was 10 ml). The remaining
HS GAGs were measured with ELISA (in vitro assay).
Flatmount analyses
The flatmount analyses were performed as previously described,
with minor modifications (49). Briefly, the eyes were fixed in 4%
paraformaldehyde for 2 hours and were stained overnight with FITC-
labeled Griffonia simplicifolia lectin (GS; a marker for vessels and
microglia/macrophages; 1:100; Sigma-Aldrich Corp.). A single image
that captured the entire retinal flatmount was obtained with a confocal
microscope (Nikon, Tokyo, Japan) for each specimen. The areas of
avascular retina and extra-retinal NV relative to the entire retinal were
determined using Photoshop CS (Adobe Systems, San Jose, CA, USA).
Real-time PCR
Total RNA was extracted with Trizol (Invitrogen) after tissue
homogenization according to the manufacturer’s instruction.
Purified RNA (1 mg) was treated with DNase I (Invitrogen) and
cDNA was synthesized with reverse transcriptase (Invitrogen) and
5 mmol/L random hexamer. Real-time PCR was performed and
analyzed using the SYBR Green I format on the Light Cycler
rapid thermal cycler system (ST300, Roche Diagnostics Ltd,
Lewes, UK) according to the manufacturer’s instructions.
Reactions were performed using the SYBR Green reaction mix
(Qiagen, Valencia, CA, USA) with 0.5 mmol/l primers. Murine
Cyclophilin A RNA was used as a standard for normalization. The
sequences of the PCR primer pairs were mVegf, 59 -TTA CTG
CTG TAC CTC CAC C-39 (forward) and 59 -ACA GGA CGG
CTT GAA GAT G-’ (reverse) and mCyclophilin A, 59-CAG ACG
CCA CTG TCG CTT T-39 (forward) and 59 -TGT CTT TGG
AAC TTT GTC TGC AA-39 (reverse). Samples that do not meet
desirable PCR quality and specificity verified by melting-curve
dissociation analysis were excluded from the analyses. For
quantification, a standard curve was generated from a cDNA
template for each gene. Titrations were performed to ensure that
PCR were carried out in the linear range of amplification. Relative
transcript levels of each gene were calculated using the second
derivative maximum values from the linear regression of cycle
number versus log concentration of the amplified gene. The
amount of mVegf RNA was expressed as fold change relative to
the number of copies measured for mCyclophilin A RNA (mean 6
S.E.M.) from the same retina treated with heparin (N=6) or PBS
(N=5). Comparable results were obtained in a replicate
experiment using a different set of mice.
In vitro VEGF-A degradation assay
Various amounts of murine plasmin (3.2, 16, 80, or 400 ng)
were added to recombinant VEGF165 (20 ng) or VEGF121
(20 ng) with or without heparin (100 mg) in a reaction buffer
(100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM
Dithiothreitol). The prepared samples were incubated at 37uC
overnight and were subjected to western blotting using anti-
VEGF-A antibody (sc-507; 1:500; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA), as described above.
HUVEC proliferation assay
HUVECs purchased from Kurabo Biomedical (Osaka, Japan)
were used in passages 3 to 5. Cells in EG2 media that contained
epidermal growth factor (10 ng/ml), hydrocortisone (1 mg/ml),
basic fibroblast growth factor (3 ng/ml), and heat-inactivated fetal
bovine serum (1%) (all from Kurabo Biomedical), PBS, or porcine
ocular fluid were seeded into 96-well plates (5,000 cells/100 ml/
well) and incubated at 37uC. After 2 hours, heparin, VEGF-A
(Kurabo Biomedical), or PBS was added to the medium. Cells
were incubated for total of 48 hours before tetrazolium-based dye
(WST-1; Promega Corp., Fitchburg, WI, USA) was applied. The
amount of fromazan dye produced (reflecting the number of the
viable cells) was measured with a plate reader (Bio-Rad
Laboratories) 4 hours later.
HUVEC scratch assay
After HUVECs were harvested by trypsin-EDTA (Kurabo
Biomedical), cells were seeded in a 24-well plate in EG2 media
(1,500 cells/800 ml/well). After cells reached confluence, VEGF-A
(1 ng/ml) was added together with or without heparin in fresh
EG2 or ocular fluid as medium. Six hrs later, HUVECs were
wounded with a pipet chip by creating a ‘‘groove’’ in the center of
well and incubated further in the same medium. The migration of
the cells was stopped 24 hrs later by exchanging the medium with
4% paraformaldehyde. After cells were fixed for 20 minutes, cells
were gently washed twice with PBS, and stained with 0.001%
toluidine blue (Sigma-Aldrich Corp.) for 60 min. The diameter of
the wound was measured from 10 areas spaced 0.71 mm from
each other and averaged.
HUVEC tube-formation assay
ECMatrix
TM (Millipore Corp., Billerica, MA, USA) were
applied to a 96-well plate (45 ml/well) in a cold room (4uC),
which were solidified by transferring the plate in 37uC for 1 hr.
After HUVECs were harvested by trypsin-EDTA (Kurabo
Biomedical), cells were seeded into the matrix-coated 96-well
plate in triplicate (5610
3 cells/150 ml/well). EGM2 media or
ocular fluid was supplemented with VEGF-A (1 ng/ml) with or
without heparin and used as medium. The cells were incubated for
3.0 hrs at 37uC and tube formation was stopped by exchanging
the medium with 4% paraformaldehyde. After cells were fixed for
20 minutes, cells were gently washed twice with PBS, and stained
with 0.001% toluidine blue (Sigma-Aldrich Corp.) for 60 min. The
number of branch points and length of formed tubular structures
were quantified from 4 mm64 mm field focused in the center of
the well.
HUVEC-VEGF-165 binding assay
Fluorokine biotinylated VEGF-A (R&D Systems) was used for
cell-based binding assay according to the provider’s protocol. In
brief, biotinylated VEGF-165 (10 ml) was added to HUVECs
(1610
5 cells/25 ml). As a negative control, an identical sample of
cells was stained with 10 ml biotinylated negative control reagent.
After the samples were incubated for 60 minutes on ice,10 ml
avidin-fluorescein isothiocyanate (FITC) was added to each
sample, and the reaction mixture was incubated for an additional
GAGs in Retinal Angiogenesis
PLoS ONE | www.plosone.org 11 October 2010 | Volume 5 | Issue 10 | e1349330 minutes on ice. Then, the cells were washed twice with 1 ml of
wash buffer (RDF1 buffer) and suspended in 0.25 ml of the same
buffer. The stained cells were analyzed using FACS Cailbur
(Becton Dickinson, San Jose, CA,USA).
In vitro binding assays
The carboxyl terminals of heparin (10 mg/well unless designat-
ed otherwise), VEGFR1 (200 ng/well), or VEGFR2 (200 ng/well)
were covalently attached to the 96-well plate coated with
aminoacids (Takara Bio Inc., Shiga, Japan) at 4uC for 4 hours
using ethyl-carbodiimide hydrochloride (20 mg/ml; Pierce Bio-
technology, Rockford, IL, USA) as a crosslinker. After adding the
blocking buffer (Takara Bio Inc.), the mixtures of VEGF-A
(200 ng/ml unless designated otherwise) and heparin, HS, or the
ocular fluid (100 ml/well) were applied to each well and were
incubated at 4uC overnight. The plate was rinsed on ice with cold
PBS and the amount of VEGF-A bound to VEGFRs was
measured using components of a human VEGF ELISA kit
(R&D Systems Inc.) according to the manufacturer’s instructions,
with following modifications. We used ice cold PBS for washing
instead of washing buffer included in the kit and all the procedures
were conducted at 4uC until the final washing step was completed.
Finally, the plates were analyzed by measuring absorbance at
450 nm (reference at 620 nm) using a plate reader.
Supporting Information
Figure S1 Injection of soluble VEGFR1 (sVEGFR1) terminates
the development of NV in murine OIR. sVEGFR1 (0.5 mg/
0.5 ml/eye; R&D systems), a potent antagonist of VEGF-A, was
injected into one eye and PBS in the other at P12 in murine OIR
models (N=8). The retinal fat-mounts stained with GS lectin were
subjected to analyses. Representative images of PBS-treated and
sVEGFR1-treated eyes are shown (A and B, respectively). The
areas of NV (red) and avascular retina (blue) relative to the entire
retina (examples are shown in C and D) were quantified and
expressed in percentages (E and F, respectively). NV was nearly
extinguished at P17 in sVEGFR1-treated eyes (E; reduction of NV
by 98.0% compared to PBS-treated eyes), while no difference was
seen in the areas of avascular retina (F). All statistical data are
expressed as mean 6 S.E.M.
Found at: doi:10.1371/journal.pone.0013493.s001 (7.85 MB TIF)
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